Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 12/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13906271 | 1.00 | SCN9A (0.51) | SCN9AMAP2K1GPR119ALOX5APFEN1 | |
| SCHEMBL13906269 | 0.95 | MAP2K1 (0.47) | SCN9AMAP2K1GPR119ALOX5APFEN1 | |
| SCHEMBL1111233 | 0.95 | MAP2K1 (0.47) | SCN9AMAP2K1GPR119ALOX5APFEN1 | |
| SCHEMBL12869543 | 0.95 | MAP2K1 (0.47) | SCN9AMAP2K1GPR119ALOX5APFEN1 | |
| SCHEMBL13915452 | 0.94 | MAP2K1 (0.47) | SCN9AMAP2K1GPR119 | |
| SCHEMBL1141629 | 0.92 | MAP2K1 (0.47) | SCN9AMAP2K1GPR119 | |
| SCHEMBL13906303 | 0.88 | MAP2K1 (0.66) | SCN9AMAP2K1 | |
| SCHEMBL1111324 | 0.88 | MAP2K1 (0.66) | SCN9AMAP2K1 | |
| SCHEMBL1111489 | 0.85 | EPHA2 (0.45) | MAP2K1GPR119 | |
| SCHEMBL13906273 | 0.85 | EPHA2 (0.45) | MAP2K1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-24 | — | — | US | claimed |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | claimed |
| EP-2279166-A1 | SUBSTITUTED PHENOXYBENZAMIDES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-02 | — | — | EP | claimed |
| EP-2155659-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-24 | — | — | EP | claimed |
| WO-2009129938-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-29 | — | — | WO | claimed |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2009-03-26 | — | — | US | claimed |
| WO-2008138639-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-20 | — | — | WO | claimed |
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071125-A1 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY | MKI67, CDK4, VHL | SCN9A 4716/4885MAP2K1 141/4885GPR119 1193/4885 |
| US-20110039819-A1 | SUBSTITUTED PHENOXYBENZAMIDES | CCNB3, VEGFA, CCND2 | SCN9A 3613/4885MAP2K1 3245/4885GPR119 289/4885 |
| US-20090082328-A1 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity | MKI67, CDK4, VHL | SCN9A 4716/4885MAP2K1 141/4885GPR119 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.